A5000200605- Bladder and Urothelial Cancer Treatments
- Urinary and Genital Oncology Studies
- Kidney Stones and Urolithiasis Treatments
- Urological Disorders and Treatments
- Renal cell carcinoma treatment
- Urinary Bladder and Prostate Research
- Urinary Tract Infections Management
- Minimally Invasive Surgical Techniques
- Surgical Simulation and Training
- Epigenetics and DNA Methylation
- Pediatric Urology and Nephrology Studies
- Ureteral procedures and complications
- Renal and Vascular Pathologies
- Infectious Disease Case Reports and Treatments
- Cancer Research and Treatments
- Prostate Cancer Diagnosis and Treatment
- Pelvic floor disorders treatments
- Cardiac, Anesthesia and Surgical Outcomes
- Renal and related cancers
- Amino Acid Enzymes and Metabolism
- Opioid Use Disorder Treatment
- Cancer Immunotherapy and Biomarkers
- Therapeutic Uses of Natural Elements
- Esophageal Cancer Research and Treatment
- Testicular diseases and treatments
University of Iowa
2015-2025
University of Iowa Health Care
2022-2025
The University of Texas Southwestern Medical Center
2018-2024
University of Iowa Hospitals and Clinics
2014-2024
Iowa City VA Health Care System
2024
Southwestern Medical Center
2020
Nashville Oncology Associates
2020
Madison Group (United States)
2020
Iowa City Public Library
2015-2020
The Lane Libraries
2017
Due to the ongoing bacillus Calmette-Guérin (BCG) shortage, sequential intravesical gemcitabine and docetaxel has been increasingly used as first-line therapy for high-risk non-muscle-invasive bladder cancer (NMIBC). However, data directly comparing these 2 therapies are lacking.To compare outcomes of patients with NMIBC treated vs BCG.This retrospective cohort study was conducted from January 1, 2011, December 31, 2021. The median (IQR) duration follow-up 23 (12-33) months receiving 49...
No AccessJournal of UrologyAdult Urology1 May 2020Multi-Institution Evaluation Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder CancerThis article is commented on by the following:Editorial Comment Ryan L. Steinberg, Lewis J. Thomas, Nathan Brooks, Sarah Mott, Andrew Vitale, Trafford Crump, Mounica Y. Rao, Marcus Daniels, Jonathan Wang, Supriya Nagaraju, William C. DeWolf, Donald Lamm, Max Kates, M. Eric Hyndman, Ashish Kamat, Trinity Bivalacqua, Kenneth...
Bacillus Calmette-Guérin (BCG) is currently recommended as adjuvant therapy following complete transurethral resection of bladder tumor for high-risk nonmuscle-invasive cancer (NMIBC). In response to the BCG shortage, gemcitabine plus docetaxel (Gem/Doce) has been utilized at our institution in BCG-naïve setting. We report outcomes patients with NMIBC treated Gem/Doce.We retrospectively reviewed Gem/Doce from May 2013 through April 2021. Patients received 6 weekly intravesical instillations...
Bacillus Calmette-Guerin (BCG) is the most effective intravesical therapy for non-muscle invasive bladder cancer (NMIBC), but patients can fail or supply shortages develop. For BCG failures, radical cystectomy recommended. However, in who desire preservation are poor surgical candidates, alternative salvage therapies should be explored.To determine whether dual sequential gemcitabine and docetaxel treating NMIBC.We evaluated our initial experience with 45 treated between June 2009 May 2014....
Abstract Background Post-procedural antimicrobial prophylaxis is not recommended by professional guidelines but still commonly prescribed and can lead to patient harm. The goal of this multicenter pilot intervention trial was encourage less frequent use post-procedural antimicrobials after common endoscopic urologic procedures.Table 1.Characteristics patients across the 3 participating hospitals during both baseline periods Methods We evaluated a bundled using pre-post, quasi-experimental...
Clinical practice guidelines recommend adjuvant intravesical BCG for high-risk and, in many cases, intermediate-risk non-muscle-invasive bladder cancer (NMIBC) [1, 2]. However, induction is generally delayed 2–4 weeks following transurethral resection of tumour (TURBT) to allow re-epithelisation and mitigate the risk disseminated infection [2-4]. In contrast, early use chemotherapy TURBT carries minimal theoretical observed 5]. do not explicitly any prescribed waiting period post-TURBT,...
Objectives Sonoporation uses ultrasound (US) and contrast agents (UCAs) to enhance cell permeabilization, thereby allowing delivery of therapeutic compounds non-invasively into specific target cells. The objective this study was elucidate the biophysical mechanism sonoporation, specifically role UCAs as well exposure frequency. inertial cavitation (IC) thresholds lipid-shelled octafluoropropane UCA were directly compared levels generated sonoporation determine involvement in producing...
Objective: To create the first data-driven definition for those unlikely to benefit from further BCG treatment.Materials and Methods: The database created Phase 2 BCG-Interferon-␣ 2B (IFN) study was queried failure patients were identified (n = 334).Full protocols have previously been published.Separate models constructed analysis of with any CIS (pure or concomitant) pure papillary disease.Variables considered included age, gender, stage, grade, tumor size focality (for only), number prior...
Introduction: Tissue retraction during minimally invasive surgery has been achieved to date with patient positioning or additional instrumentation. The Levita™ Magnetic Surgical System (San Mateo, CA), a novel, noninvasive, magnetic device for surgery, used facilitate reduced-port robotic prostatectomy using multiport platform. With the release of da Vinci SP system (Intuitive, Sunnyvale, we now report multi-institutional initial case series magnet-assisted single-port Materials and Methods:...